Medical device company Vero Biotech received $65 million from Horizon Technology Finance and Monroe Capital, Vero Biotech board director Todd Brady tells Axios exclusively.
Why it matters: The company's portable, tankless nitric oxide delivery system aims to make it easier to treat persistent pulmonary hypertension in newborns.
